The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Darzalex Faspro-based quadruplet therapy regimen shows significant improvement in transplant-eligible newly diagnosed MM

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Data from the phase III PERSEUS study showed that a Darzalex Faspro (daratumumab and hyaluronidase-fihj)-based quadruplet induction, consolidation regimen and doublet maintenance regimen showed clinical improvement in the treatment of transplant-eligible newly diagnosed multiple myeloma. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account